calliditas.se (CALT) - Koefisien utang jangka dawa marang modal

This price chart for Calliditas Therapeutics (CALT) reflects the performance of a company developing kidney therapies, where long-term debt stands at 9.15. Risks include reliance on a single product, patent disputes, and insurance reimbursement issues. Meanwhile, the business remains insulated from economic cycles, and a steady cash flow from global sales fully covers the costs of new research and development.

The long-term debt-to-equity ratio measures the proportion of liabilities with a maturity exceeding one year relative to shareholders' equity. For Calliditas Therapeutics (CALT), this metric reflects financial stability following the completion of primary development costs for Tarpeyo. Analyzing the long-term debt-to-equity trend allows for an assessment of leverage management efficiency. Low debt levels combined with high margins in the orphan drug segment minimize bankruptcy risks, confirming the company's ability to scale its business without excessive borrowing.